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Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released by damaged solid organs. Whether
circulating cell-free MT-DNA quantitation could be used to predict the risk of poor COVID-19 outcomes remains
undetermined.
We measured circulating MT-DNA levels in prospectively collected, cell-free plasma samples from 97 subjects with
COVID-19 at hospital presentation. Our primary outcome was mortality. Intensive care unit (ICU) admission, intubation,
vasopressor, and renal replacement therapy requirements were secondary outcomes. Multivariate regression analysis
determined whether MT-DNA levels were independent of other reported COVID-19 risk factors. Receiver operating
characteristic and area under the curve assessments were used to compare MT-DNA levels with established and
emerging inflammatory markers of COVID-19.
Circulating MT-DNA levels were highly elevated in patients who eventually died or required ICU admission, intubation,
vasopressor use, or renal replacement therapy. Multivariate regression revealed that high circulating MT-DNA was an
independent risk factor for these outcomes after adjusting for age, sex, and comorbidities. We also found that circulating
MT-DNA levels had a similar or superior area under the curve when compared against clinically established measures of
inflammation and emerging markers currently of interest as investigational targets for COVID-19 therapy.
These […]
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BACKGROUND. Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released
by damaged solid organs. Whether circulating cell-free MT-DNA quantitation could be used to
predict the risk of poor COVID-19 outcomes remains undetermined.
METHODS. We measured circulating MT-DNA levels in prospectively collected, cell-free plasma
samples from 97 subjects with COVID-19 at hospital presentation. Our primary outcome was
mortality. Intensive care unit (ICU) admission, intubation, vasopressor, and renal replacement
therapy requirements were secondary outcomes. Multivariate regression analysis determined
whether MT-DNA levels were independent of other reported COVID-19 risk factors. Receiver
operating characteristic and area under the curve assessments were used to compare MT-DNA
levels with established and emerging inflammatory markers of COVID-19.
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RESULTS. Circulating MT-DNA levels were highly elevated in patients who eventually died or
required ICU admission, intubation, vasopressor use, or renal replacement therapy. Multivariate
regression revealed that high circulating MT-DNA was an independent risk factor for these
outcomes after adjusting for age, sex, and comorbidities. We also found that circulating MT-DNA
levels had a similar or superior area under the curve when compared against clinically established
measures of inflammation and emerging markers currently of interest as investigational targets for
COVID-19 therapy.
CONCLUSION. These results show that high circulating MT-DNA levels are a potential early indicator
for poor COVID-19 outcomes.
FUNDING. Washington University Institute of Clinical Translational Sciences COVID-19 Research
Program and Washington University Institute of Clinical Translational Sciences (ICTS) NIH grant
UL1TR002345.

Introduction
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has resulted in a global health emergency, causing considerable strain on economic, social, and medical systems (1). COVID-19 presents in a wide spectrum of
severity. Although most patients develop only mild or uncomplicated illness, others require prolonged
hospitalization, ICU care, and intubation for respiratory support. In severe cases, patients can develop
1
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acute respiratory distress syndrome (ARDS), cytokine storm, multiorgan failure, and death (1). Although
the underlying mechanisms of severe COVID-19 illness remain unclear, it appears to be exacerbated by
an overexuberant innate immune response (2). These observations have led to several ongoing clinical
trials targeting components of the innate immune response, such as inflammatory cytokine signaling and
complement activation (3–5).
Previous work has established that viral infection can trigger cellular necrosis, which in turn inhibits
viral replication along with amplifying antiviral immune responses through the release of damage-associated molecular patterns (DAMPs) (6). DAMPs in particular are potent triggers of innate responses through
their engagement of pattern recognition receptors, such as Toll-like receptors (TLRs), that drive the expression of inflammatory cytokines and presentation of viral antigens (7). Mitochondrial DNA (MT-DNA)
is a member of a group of mitochondrial DAMPs (MT-DAMPs) released by injured or dying cells and is
recognized by TLR9 because of encoded hypomethylated CpG motifs reminiscent of an ancestral bacterial origin (8). MT-DNA levels have been previously shown to be elevated in the plasma of patients who
develop ARDS and multiorgan dysfunction during sepsis, as well as during sterile injury, including trauma,
hemorrhagic shock, and ischemia/reperfusion (9–14). The release of MT-DNA is often accompanied by
the release of other MT-DAMPs, such as N-formylated peptides, cytochrome c, and cardiolipin, which
collectively engage multiple TLRs and the N-formylated peptide receptor-1 that in turn induce not only
inflammatory cytokine expression (15–17) but also the generation of reactive oxygen species and the facilitation of neutrophil trafficking and activation (14, 18, 19). Through these effects, MT-DAMPs can directly
contribute to acute lung injury and systemic inflammation (8). Given that ARDS secondary to SARSCoV-2 infection is also linked with lung tissue injury and immune cell activation (20), we asked if elevated
levels of circulating MT-DNA could be used as a risk indicator for the development of severe illness.
Here, we demonstrate that COVID-19 patients with high circulating levels of cell-free MT-DNA at the
time of hospital presentation are more likely to require intensive care unit (ICU) care and intubation and
are at heightened risk of death. In addition, MT-DNA quantitation as predictor of poor COVID-19 outcomes is comparable to or better than inflammation indicators commonly used in current clinical practice,
as well as certain emerging immune markers.

Results
Participants. A total of 107 subjects were assessed for eligibility from March 26, 2020, to April 26, 2020.
Of these, 97 adult subjects with laboratory-confirmed COVID-19 were included in our study (Table 1 and
Figure 1). Ten subjects were excluded because they did not have samples from the day of presentation. The
median age of the population in our study was 65 (interquartile range 54–73). Among these subjects, 55.7%
(54/97) were male and 44.3% (43/97) were female; 77.3% (75/97) were African American, 20.6% (20/97)
were White, 1% (1/97) was Middle Eastern, and 1% (1/97) was Indian; and 46.4% (45/97) were obese
(BMI ≥ 30), while 49.5% (48/97) were nonobese (BMI 18.5–29.9) and 4.1% (4/97) were underweight (BMI
< 18.5). A positive smoking history was reported in 46.4% (45/97) of subjects. The median follow-up time
was 81 days (interquartile range 74–87).
Comorbidities and outcomes. The primary outcome of mortality was observed in 25.8% (25/97) of
subjects in our study (Table 1). Those who died were older [76.2 versus 61.1 years, OR 1.08 (1.04–
1.13), P = 0.0003], were more likely to be smokers [64% versus 40.3%, OR 2.63 (1.04–7.00), P = 0.04],
and were more likely to have type 2 diabetes mellitus [72% versus 45.8%, OR 3.04 (1.17–8.64), P =
0.02], coronary artery disease [48% versus 19.4%, OR 3.8 (1.44–10.34), P = 0.007], and 2 or more
comorbidities [84% versus 56.9%, OR 5.54 (1.72–24.91, P = 0.009] on univariate analysis (Table 1).
The time to discharge for subjects who survived was mean 12.4 days, median 7 days (interquartile
range 3–18), and range 1–56.
Of the subjects with COVID-19, 56.7% (55/97, Table 2) required an ICU admission. These subjects
were older [71 versus 54.4, OR 1.1 (1.06–1.15), P < 0.0001] and were more likely to have type 2 diabetes
mellitus [65.5% versus 35.7%, OR 3.41 (1.49–8.07), P = 0.004] and 2 or more comorbidities [72.7% versus
52.4%, OR 2.66 (1.14–6.38), P = 0.02]. As expected, the time to discharge was higher for patients requiring
ICU admission [15 days (interquartile range 5–28), n = 27; versus 5 days (interquartile range 3–12.5), n =
36, P = 0.0012]. Among patients, 25.8% (25/97) required invasive mechanical ventilation as a treatment
for acute respiratory failure. The main clinical characteristic associated with higher risk for intubation was
age, with a median of 70 years for intubated subjects compared with 61 years for nonintubated subjects
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Table 1. Demographic and clinical characteristics associated with mortality
Demographics
Age, yA
Male n (%)B
Female n (%)B
African AmericanB
BMIA
Smoking historyB
Comorbidities
HTNB
DMIIB
COPDB
CKD > 2B
ESRDB
CADB
CVAB
VTEB
Two or more comorbiditiesB
Three or more comorbiditiesB

Total (n = 97)

Alive (n = 72)

Deceased (n = 25)

OR for mortality (95% CI)

P value

65 (54–73)
54 (55.6)
43 (44.3)
75 (77.3)
29.1 (24.7–34.4)
45 (46.3)

61.1 (50.3–70.5)
39 (54.17)
33 (45.83)
57 (79.2)
28.9 (24.7–33.3)
29 (40.3)

76.2 (65.3–84.9)
15 (60)
10 (40)
18 (72)
30.9 (24.5–37.6)
16 (64)

1.08 (1.04–1.13)
1.26 (0.5–3.27)

0.0003
0.6

0.6 (0.24–2)
1.02 (0.96–1.08)
2.63 (1.04–7)

0.4
0.4
0.04

73 (75.2)
51 (52.5)
13 (14.4)
37 (38.1)
8 (8.2)
26 (26.8)
21 (21.6)
16 (16.4)
62 (63.9)
50 (51.5)

51 (70.8)
33 (45.8)
7 (9.7)
24 (33.3)
4 (5.6)
14 (19.4)
14 (19.4)
14 (19.4)
41 (56.9)
32 (43.8)

22 (88)
18 (72)
6 (24)
13 (52)
4 (16)
12 (48)
7 (28)
2 (8)
21 (84)
18 (75)

3.02 (0.91–13.71)
3.04 (1.17–8.64)
2.93 (0.85–9.89)
2.16 (0.85–5.53)
3.23 (0.71–14.80)
3.8 (1.44–10.34)
1.61 (0.54–4.53)
0.36 (0.05–1.42)
5.54 (1.72–24.91)
3.21 (1.23–9.15)

0.09
0.02
0.08
0.1
0.1
0.007
0.3
0.2
0.009
0.02

Continuous variables are reported as median (interquartile range). P values indicate differences between alive and deceased COVID-19 patients. Races of
participants: 77.3% were African American, 20.6% were White, 1% was Middle Eastern, and 1% was Indian. AValues presented as median and interquartile
range. BValues presented as number and percentage of the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive
pulmonary disease; CKD > 2, chronic kidney disease; ESRD, end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE,
venous thromboembolism.

[OR 1.05 (1.01–1.09), P = 0.005] on univariate analysis (Table 3). As expected, the time to discharge was
higher for patients who required intubation [27.5 days (interquartile range 18.5–38.5), n = 12; versus 5 days
(interquartile range 3–13), n = 51, P < 0.0001].
COVID-19 patients with high circulating MT-DNA are at higher risk for mortality. To assess MT-DNA levels
in COVID-19 patients, we utilized a previously established in situ quantitative PCR method (14) to measure
the accumulation of fragments derived from the mitochondrial encoded gene cytochrome b (MT-CYTB)
within cell-free circulating plasma. Plasma MT-CYTB levels were elevated in those subjects who died from
COVID-19 [7.56 (7.15–7.81, n = 25)] compared with those who survived [7.23 (7.050–7.485), n = 72, P
= 0.008, Figure 2A] and were associated with an increased risk for mortality on univariate logistic regression (OR 2.24, 95% CI 1.29–4.16, P = 0.006). For MT-CYTB, area under the curve (AUC) for mortality
was 0.68 (95% CI 0.54–0.81, Figure 2B). On multivariable logistic regression, plasma MT-CYTB levels
remained an independent risk factor for mortality when adjusted for age, sex, and 2 or more comorbidities
(ORadj, 2.19, 95% CI 1.19–4.28, P = 0.015, Table 4). Levels of mitochondrial cytochrome c oxidase III
(MT-COX3), another MT-DNA–encoded gene (Supplemental Figure 1B; supplemental material available
online with this article; https://doi.org/10.1172/jci.insight.143299DS1), revealed an increased trend in
subjects who died [5.63 (5.00–6.46), n = 25] relative to those who survived [5.32 (4.90–5.83), n = 72] but
did not reach statistical significance (P = 0.1).
COVID-19 patients with high circulating MT-DNA are more likely to require ICU admission and intubation.
Plasma MT-CYTB levels were elevated in those subjects with COVID-19 who required an ICU admission [7.52 (7.14–7.72), n = 55] compared with those who were not admitted to the ICU [7.13 (7.00–7.31),
P < 0.0001, n = 42, Figure 3A]. MT-CYTB levels were associated with ICU admission on univariate
logistic regression (OR 4.25, 95% CI 2.15–9.59, P = 0.0001). For MT-CYTB, AUC for ICU admission
was 0.75 (95% CI 0.65–0.85, Figure 3B). On multivariable logistic regression, plasma MT-CYTB levels
remained an independent risk factor for ICU admission after adjusting for age, sex, and 2 or more comorbidities (ORadj, 3.97, 95% CI 1.83–10.34, P = 0.002, Table 5). Notably, we also made similar findings
for MT-COX3 [Supplemental Figure 1C; ORadj for age, sex, and 2 or more comorbidities, 1.47; 95% CI
1.14–1.95; P = 0.005; AUC of COX3 for ICU admission 0.69 (95% CI 0.58–0.79)].
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Figure 1. CONSORT flow diagram showing enrollment of patients, allocation, and outcomes. RRT, renal replacement therapy.

Additionally, plasma MT-CYTB levels were elevated in those subjects with COVID-19 who
required intubation [7.69 (7.54–8.07, n = 25)] versus those who did not require intubation [7.18
(7.033–7.438), n = 72, P < 0.0001, Figure 3C]. Plasma MT-CYTB levels were associated with intubation on univariate logistic regression (OR 9.12, 95% 3.77–28.56, P < 0.0001). For MT-CYTB, AUC
for intubation was 0.86 (95% CI 0.76–0.95, Figure 3D). On multivariable logistic regression, plasma
MT-CYTB levels remained an independent risk factor for intubation (ORadj, 8.47, 95% CI 3.49–27.33,
P < 0.0001, Table 6). Similar findings were observed with MT-COX3 [Supplemental Figure 1D; ORadj
for age, sex, and 2 or more comorbidities, 2.69; 95% CI 1.77–4.74; P < 0.0001; AUC for intubation
0.80 (95% CI 0.69–0.91)].
COVID-19 patients with high circulating MT-DNA are more likely to require vasopressors and renal replacement therapy. Plasma MT-CYTB levels were also elevated in those subjects with COVID-19 who
ultimately had end organ dysfunction requiring vasopressors [7.63 (7.35–8.02), n = 29] compared
with those who did not require vasopressors [7.20 (7.04–7.43), P < 0.0001, n = 68, Figure 4A]. For
MT-CYTB, AUC for vasopressor requirement was 0.80 (95% CI 0.69–0.91, Figure 4B). Similarly, plasma MT-COX3 levels were elevated in subjects requiring vasopressors [5.98 (5.25–6.68), n = 29; compared with 5.25 (4.85–5.70), P = 0.0001, n = 68 (Supplemental Figure 1E); AUC of COX3 for vasopressor requirement was 0.74 (95% CI 0.62–0.86)]. Notably, plasma MT-CYTB levels on admission
were also elevated in subjects who had end organ dysfunction requiring RRT while in the ICU [7.75
(7.64–8.08), n = 14] compared with those who did not require RRT [7.2 (7.04–7.47), P < 0.0001, n =
81, Figure 4C]. For MT-CYTB, AUC for RRT requirement was 0.95 (95% CI 0.91–0.99, Figure 4D).
Similarly, plasma MT-COX3 levels were elevated in subjects who required RRT [6.59 (6.36–7.12), n =
14] compared with those who did not require RRT [5.24 (4.81–5.69), P < 0.0001, n = 81] (Supplemental Figure 1F); AUC of COX3 for RRT requirement was 0.94 (95% CI 0.88–0.99)].
Circulating MT-DNA levels show similar or improved sensitivity over clinically established measurements of
inflammation used in COVID-19 patients. Plasma MT-CYTB levels had a similar AUC for mortality when
compared with lactic acid dehydrogenase (LDH), ferritin, or D-dimer levels and were better than C-reactive
protein (CRP) drawn within the first 24 hours of presentation (Figure 5A). Importantly, the AUC for plasma MT-CYTB levels was superior to CRP, LDH, ferritin, and D-dimer levels when predicting the need for
an ICU admission (Figure 5B) or intubation (Figure 5C). A similar pattern was identified for MT-COX3
when compared with CRP, LDH, ferritin, and D-dimer levels for predicting the need for an ICU admission
(Supplemental Figure 2B) and inferior for predicting mortality (Supplemental Figure 2A) but was superior
to these clinically utilized markers for the need for intubation (Supplemental Figure 2C).
Circulating MT-DNA levels correlate with other emerging markers of COVID-19 severity. Plasma MT-CYTB
levels moderately correlated with concurrently measured levels of IL-6, which has been implicated
in the pathogenesis of COVID-19 (r = 0.39, 95% CI 0.196–0.555, P = 0.0001, n = 92, Figure 6A).
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Table 2. Demographic and clinical characteristics associated with ICU admission
Demographics
Age, yA
Male n (%)B
Female n (%)B
African AmericanB
BMIA
Smoking historyB
Comorbidities
HTNB
DMIIB
COPDB
CKD > 2B
ESRDB
CADB
CVAB
VTEB
Two or more comorbiditiesB
Three or more comorbiditiesB

No ICU (n = 42)

ICU (n = 55)

OR for ICU (95% CI)

P value

54.4 (38.5–64.2)
19 (45.2)
23 (54.76)
33 (78.6)
30.2 (25.3–34.8)
15 (35.7)

71 (63.8–78.9)
35 (63.6)
20 (36.36)
42 (76.4)
28.4 (24.4–33)
30 (54.5)

1.1 (1.06–1.15)
2.11 (0.93–4.86)

<0.0001
0.07

0.88 (0.32–2.29)
0.98 (0.92–1.03)
2.16 (0.95–5)

0.8
0.5
0.067

29 (69)
15 (35.7)
6 (14.3)
12 (28.6)
4 (9.5)
8 (19.1)
7 (16.7)
8 (19.1)
22 (52.4)
16 (38.1)

44 (80)
36 (65.5)
7 (12.7)
25 (45.5)
4 (7.3)
18 (32.7)
14 (25.5)
8 (14.6)
40 (72.7)
34 (61.8)

1.79 (0.7–4.61)
3.41 (1.49–8.07)
0.87 (0.26–2.93)
2.08 (0.89–5)
0.74 (0.16–3.33)
2.06 (0.81–5.61)
1.7 (0.63–4.94)
0.72 (0.24–2.15)
2.66 (1.14–6.38)
2.63 (1.16–6.11)

0.2
0.004
0.8
0.09
0.7
0.1
0.3
0.5
0.02
0.02

Continuous variables are reported as median (interquartile range). P values indicate differences between not ICU and ICU admitted COVID-19 patients. Data
not available for non–African American participants. AValues presented as median and interquartile range. BValues presented as number and percentage of
the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CKD > 2, chronic kidney disease; ESRD,
end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE, venous thromboembolism.

Similarly, MT-CYTB levels highly correlated with plasma soluble C5b-9, which is a marker of complement activation and suggests the formation of a membrane attack complex (MAC) (r = 0.49, 95%
CI 0.32–0.64, P < 0.0001, n = 95, Figure 6B). MT-CYTB also correlated with the neutrophil-to-lymphocyte ratio (r = 0.37, 95% CI 0.17–0.54, P = 0.0003, n = 90, Figure 6C). Plasma MT-CYTB levels
had a similar or improved accuracy compared with IL-6 for mortality (Supplemental Figure 3A), ICU
admission (Supplemental Figure 3B), and intubation (Supplemental Figure 3C).
We also observed significant correlations with other biomarkers that have been implicated in the pathogenesis of COVID-19, such as CXCL9 (r = 0.31, 95% CI 0.11–0.49, P = 0.002, n = 93, Figure 6D), CCL2
(r = 0.25, 95% CI 0.05–0.44, P = 0.01, n = 93, Figure 6E), CXCL10 (r = 0.25, 95% CI 0.05–0.44, P = 0.01,
P = 94, Figure 6F), IL-1RA (r = 0.43, 95% CI 0.25–0.59, P < 0.0001, n = 94, Figure 6G), and IL-2R (r =
0.27, 95% CI 0.07– 0.46, P = 0.007, P = 93, Figure 6H). Similarly, the levels of HGF highly correlated with
MT-CYTB in COVID-19 (r = 0.47, 95% CI 0.29–0.62, P < 0.0001, n = 94, Figure 6I).

Discussion
Here we observe that high levels of circulating MT-DNA are an early independent risk factor for severe illness
and mortality in hospitalized patients with COVID-19, after adjusting for age, sex, and comorbidities. Importantly, we made similar findings for 2 MT-DNA genes, MT-CYTB and MT-COX3, although the latter target
did not reach significance for mortality risk. The reasons for this incongruence are not clear. One possibility is
the accumulation of heteroplasmic mitochondrial genome deletions or point mutations that could prevent or
attenuate PCR primer recognition (21). Heteroplasmic DNA deletions have been repeatedly demonstrated to
accumulate with age within the MT-COX3 gene (22–24), and to a lesser degree, within the MT-CYTB locus,
due to age-related defects of mitochondrial DNA polymerase proofreading capability (25, 26).
Although our studies were not specifically designed to identify the mechanisms that drive peripheral blood
MT-DNA accumulation, significant correlations between LDH and IL-6 with MT-DNA levels point to a potential deleterious role for cellular necrosis in COVID-19 pathophysiology. LDH release and IL-6 production are
reported indicators of cellular necrosis (27, 28). A specific form of necrosis, necroptosis, has been demonstrated
to induce the release of damaged mitochondria (29). Necroptosis is characterized by the eventual loss of plasma
membrane integrity due to the kinase activity of the receptor-interacting proteins 1 (RIPK1) and RIPK3 (30)
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Table 3. Demographic and clinical characteristics associated with intubation
Demographics
Age, yA
Male n (%)B
Female n (%)B
African AmericanB
BMIA
Smoking historyB
Comorbidities
HTNB
DMIIB
COPDB
CKD > 2B
ESRDB
CADB
CVAB
VTEB
Two or more comorbiditiesB
Three or more comorbiditiesB

Not intubated (n = 72)

Intubated (n = 25)

OR for intubation (95% CI)

P value

61 (50.35–71.9)
38 (52.8)
34 (47.22)
56 (77.8)
28.9 (24.4–34.8)
32 (44.5)

69.8 (63.9–78.5)
16 (64)
9 (36)
19 (76)
29.7 (25–32.9)
13 (52)

1.05 (1.01–1.09)
1.59 (0.63–4.19)

0.005
0.3

0.9 (0.31–2.81)
1.0 (0.94–1.06)
1.35 (0.54–3.4)

0.8
0.9
0.5

53 (73.6)
36 (50)
8 (11.1)
25 (34.7)
5 (6.9)
17 (23.6)
14 (19.4)
13 (18)
44 (61.1)
34 (47.2)

20 (80)
15 (60)
5 (20)
12 (48)
3 (12)
9 (36)
7 (28)
3 (12)
18 (72)
16 (64)

1.43 (0.49–4.70)
1.5 (0.6–3.87)
2.0 (0.55–6.71)
1.73 (0.68–4.39)
1.82 (0.35–8.07)
1.82 (0.66–4.82)
1.61 (0.54–4.53)
0.61 (0.13–2.14)
2.01 (0.74–6.08)
1.98 (0.79–5.25)

0.5
0.4
0.3
0.2
0.4
0.2
0.4
0.5
0.2
0.2

Continuous variables are reported as median (interquartile range). P values indicate differences between not intubated and intubated COVID-19 patients.
Data not available for non–African American participants. AValues presented as median and interquartile range. BValues presented as number and
percentage of the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CKD > 2, chronic kidney
disease; ESRD, end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE, venous thromboembolism.

and has been reported to act as a host defense mechanism when apoptotic death pathways are disabled by viral
infection (31). For example, in a mouse model of influenza infection, necroptosis was shown to inhibit viral
replication but with deleterious consequences to bronchial epithelial integrity (32). In humans, both H5N1 and
H1N1 influenza–induced ARDS have been shown to be associated with necrotic cell death within the distal
pulmonary epithelia (33, 34). Intriguingly, the accessory protein open reading frame 3a (Orf3a) expressed within
the highly related SARS-CoV-1 genome has been recently demonstrated to induce necroptosis through activating RIPK3 (35). SARS-CoV-2 also expresses an Orf3a accessory protein (36). However, whether SARS-CoV-2
Orf3a promotes necroptosis has yet to be determined. Some MT-DNA release may also result from innate
immune cell activation. For example, human neutrophils following activation extrude their MT-DNA due to
an inability to complete mitophagy (37). Additionally, neutrophil extracellular traps (NETs), which have been
found in the peripheral circulation of COVID-19 patients (38), are rich in MT-DNA (39). Neutrophils have also
been identified as undergoing metabolic reprogramming in the context of SARS-CoV-2 (40). In addition to neutrophils, activated platelets also release mitochondria (41), which in turn can induce NET generation, possibly
contributing to pulmonary prothrombotic complications observed in patients with severe COVID-19 illness (42).
Additionally, MT-DNA has been shown to directly promote NETosis (43, 44). The source and mechanisms of
MT-DNA release in response to SARS-CoV-2 infection are the subject of future investigation.
Multiple clinically established biomarkers, such as LDH, ferritin, CRP, and D-dimer, are currently
being evaluated to assess the risk of clinical deterioration from a COVID-19 diagnosis (40, 45–49). However, as products of gene expression in response to both acute and chronic stimuli, they tend to be largely
nonspecific measures of systemic inflammation, with the exception of LDH, a marker of cell death. Nevertheless, LDH can also be released by cells undergoing apoptosis, a predominantly antiinflammatory form
of cell death (50). Ferritin is primarily produced by the liver and serves as an acute phase reactant. Similarly, D-dimer is a nonspecific test and provides us minimal insight into the underlying pathophysiology of the
disease or events occurring at the cellular level. In contrast, there are accumulating observations that high
amounts of MT-DNA release are specifically generated by necrotic cells (51). Additionally, high MT-DNA
levels have been shown to be associated with acute lung injury, in multiple independent cohorts (12, 13, 52).
In our cohort, although CYTB performed similarly to ferritin/D-dimer for mortality, it performed better
than these markers in the context of identifying those at risk for an ICU admission or intubation, which
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Figure 2. High circulating MT-DNA levels predict a higher risk of mortality in COVID-19 patients. Plasma for
determination of circulating levels of MT-CYTB was obtained at time of hospital presentation. (A) Box-and-whisker
plots of MT-CYB levels in relation to mortality status in COVID-19 patients. The box plots depict the minimum and
maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the
interquartile range. (B) Receiver operating characteristic (ROC) curves in predicting the outcome mortality based on
MT-CYTB levels. Statistical significance was determined using Mann-Whitney U test (**P < 0.01).

are important resource utilization metrics. Moreover, we observed that MT-DNA levels were approximately 5-fold higher in COVID-19 patients who developed severe pulmonary dysfunction or eventually died,
suggesting it is at least as sensitive a biomarker as other clinically established and exploratory indicators
used in prediction models. To conduct plasma MT-DNA measurements, we employed a rapid PCR assay
technique that takes about 60 minutes to complete because of the elimination of the DNA purification
step. In resource-limited settings, this can be especially important given the current necessity to identify
subjects at a higher risk of clinical deterioration. Additionally, PCR-based assays measuring MT-DNA tend
to be less cost prohibitive and do not need specialized equipment, facilitating easy implementation. For
the abovementioned reasons, we suggest that MT-DNA be investigated as an adjunct clinical biomarker
in COVID-19. Nevertheless, whether MT-DNA levels are equivalent or better measures than routinely
obtained laboratory measurements will require additional validation with independent cohorts.
Based on our data from this study, it is not possible to clearly determine if circulating MT-DNA contributes to the pathogenesis of COVID-19. Nevertheless, cell-free MT-DNA is itself a signatory marker for the
release of other MT-DAMPs, which collectively drive proinflammatory cytokine expression through the
engagement of pattern recognition receptors on innate immune cells (7). MT-DAMPs drive IL-6 expression
by macrophages (29) and stimulate IL-8 release by neutrophils (9). Notably, IL-6 suppresses lymphopoiesis (53) while IL-8 promotes neutrophil release from the bone marrow (54) and, therefore, could possibly
explain our observed correlation between MT-DNA levels and elevations in the neutrophil-to-lymphocyte
ratio. We additionally noted a significant correlation between MAC and MT-DNA levels. Extracellular
mitochondria have been reported to activate complement. Mannose-binding lectin has been observed to
bind to cell-free mitochondria, resulting in C3 consumption in the peripheral blood of mice (55). Therefore, it is interesting to note that C3 consumption is a general sign of C3 convertase activity, which would

Table 4. Multivariate analysis associated with mortality
MT-CYTB
Age
Sex (male)
Two or more comorbidities

Adjusted OR for mortality (95% CI)

P value

2.24 (1.28–4.16)
1.074 (1.026–1.131)
1.380 (0.460–4.362)
2.578 (0.611–14.200)

0.015
0.003
0.570
0.225

N = 97 (25 mortality events).

JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299

7

CLINICAL MEDICINE

Figure 3. High circulating MT-DNA levels predict a higher risk of ICU requirement and intubation in COVID-19
patients. Plasma for determination of circulating levels of MT-CYTB was obtained at time of hospital presentation.
Box-and-whisker plots of MT-CYB levels in relation to (A) ICU admission and (C) intubation in COVID-19 patients. The
box plots depict the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The
length of the box represents the interquartile range. Empty dots indicate alive patients and shaded dots indicate
deceased patients. ROC curves in predicting the outcome (B) ICU and (D) intubation based on MT-CYTB levels. Statistical significance was determined using Mann-Whitney U test (****P <.0001).

be a prerequisite for the downstream generation of membrane attack components (56). Along those lines,
complement activation has been implicated in the pathogenesis of COVID-19–related end organ damage,
including acute lung injury (57, 58), with potential therapeutic implications (5, 59). Finally, MT-DAMPs,
unlike other inflammatory markers linked to poor outcomes of COVID-19 patients, have been reported
to directly cause acute pulmonary dysfunction and tissue damage (60). Administration of MT-DAMPs
into the bloodstream or pulmonary airways of rodents promotes acute lung injury mediated by neutrophil
chemotaxis and reactive oxygen species generation to mitochondrial formylated peptides (9, 14). In these
studies, the formylated peptide receptor-1 inhibitor cyclosporine H was shown to inhibit MT-DAMP–mediated acute lung injury. Given ongoing clinical trials that target the effects of IL-6, complement activation
and NETs in COVID-19 patients (3–5, 61, 62) future approaches that block necroptosis or MT-DAMP
recognition could also be warranted.
Our study has several limitations. First, we were unable to concurrently enroll a COVID-19–negative group with severe respiratory disease. Our center, like many others, experienced a sharp decline in
hospital presentations for illnesses other than COVID-19, making it difficult to collect samples for an
adequately matched control group. Additionally, as our samples were drawn as a part of a prospective
study of SARS-CoV-2 PCR-positive patients, any other adequately matched control group would not
be entirely comparable, as not drawn concurrently. However, it is unlikely that MT-DNA levels are
considerably different between patients with COVID-19 and acute respiratory diseases arising from
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Table 5. Multivariate analysis associated with ICU admission
Adjusted OR for ICU admission (95% CI)

P value

3.97 (1.83–10.34)
1.113 (1.062–1.180)
2.060 (0.688–6.478)
0.465 (0.113–1.713)

0.002
<0.0001
0.201
0.264

MT-CYTB
Age
Sex (male)
Two or more comorbidities
N = 97 (55 ICU events).

other etiologies. For example, reports have shown that increased MT-DNA levels in critically ill patients
are significantly associated with a higher risk of developing ARDS regardless of the underlying etiology (12, 13, 52). Nakahira et al. also showed that high level of plasma MT-DNA is a general marker
of mortality risk in ICU patients (13). Additionally, more recent work from Huang et al. (52) shows
that high plasma MT-DNA levels in ARDS patients are associated with increased risk for mortality
regardless of admission diagnosis. Indeed, several emerging studies suggest that biomarkers may be
no different in subjects with COVID-19–induced lung injury versus lung injury due to other etiologies
(63). However, the strength of our study lies in an assay that can potentially identify subjects presenting with COVID-19 who are likely to develop adverse outcomes during their hospitalization, which
becomes increasingly important when resources are constrained as has been unfortunately too common
during this pandemic (64–66). Second, this study does not assess how MT-DNA correlates with viral
load in COVID-19, which is especially important in the context of deciding when to intervene with
targeted therapeutics (67–69). Therefore, further studies will be necessary to evaluate whether it may be
a predictor of response to treatment (70). Third, decision-making in the ICU changed over the course
of our enrollment. For example, there was a tendency toward intubating earlier in the course of the
critical illness in the initial months of the COVID-19 pandemic. We also lack data to support objective
measurement of disease severity at the time of presentation as can be reflected in SOFA, APACHE, or
CURB65 scores. However, we identified MT-DNA levels as a predictor of severity utilizing mortality
as a primary endpoint, then requirement of ICU admission and requirement for intubation as independent secondary endpoints. Additionally, we identified MT-DNA levels as a predictor of disease severity
utilizing requirement of vasopressors and RRT while in the ICU as independent secondary endpoints
of end organ dysfunction.
It also remains possible that our findings may not generally apply to all patients who contract
COVID-19. Members of underrepresented minority communities are at significantly higher risk for
COVID-19 infection as well as suffering its most severe outcomes. Our analysis was conducted in an
urban medical center that serves a large African American community who may have a tendency to
inherit MT-DNA variations that differ from other groups. This may be most exemplified in a recent
report that shows certain point mutations within the MT-DNA of aging African Americans are associated with decreased pulmonary maximal inspiratory pressures (MIPs) (71). However, this study also
found other point MT-DNA mutations in African Americans were associated with increased MIPs,
suggesting a more complex picture for MT-DNA variation and its link to respiratory function. Nevertheless, this MT-DNA variation was not within the primer target sequences used in our assays.
Finally, prior studies that analyzed other diseases that involve respiratory distress, such as ARDS and

Table 6. Multivariate analysis associated with intubation
MT-CYTB
Age
Sex (male)
Two or more comorbidities

Adjusted OR for intubation (95% CI)

P value

8.48 (3.48–27.33)
1.059 (1.008–1.119)
1.339 (0.381–4.920)
0.831 (0.166–4.368)

<0.0001
0.03
0.649
0.821

N = 97 (25 intubation events).
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Figure 4. High circulating MT-DNA levels predict a higher risk for end organ dysfunction requiring vasopressors
and renal replacement in COVID-19 patients. Plasma for determination of circulating levels of MT-CYTB was
obtained at time of hospital presentation. Box-and-whisker plots of MT-CYB levels in relation to (A) requirement for vasopressors and (C) renal replacement in COVID-19 patients. The box plots depict the minimum and
maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the
interquartile range. ROC curves in predicting the outcomes (B) requirement for pressors and (D) renal replacement
based on MT-CYTB levels. Statistical significance was determined using Mann-Whitney U test (****P < 0.0001).

primary lung allograft dysfunction, on populations predominantly composed of Caucasians, and to
lesser extent, underrepresented minority groups, demonstrated significant associations with cell-free
circulating MT-DNA (12–14). Taken together with our findings, these reports support a robust association with MT-DNA levels and poor outcomes from COVID-19 infection that is likely applicable to
all racial groups.
In summary, we demonstrate that MT-DNA measured early in the disease course can predict
survival status, requirement for ICU-level care, the need for endotracheal intubation, as well as end
organ dysfunction requiring vasopressors and RRT. We also show that MT-DNA levels are associated
with exploratory biomarkers implicated in the pathogenesis of COVID-19–related morbidity and mortality. Further studies will be needed to discern the contribution of MT-DAMPs such as MT-DNA to
COVID-19 pathogenesis, as well as to understand whether MT-DNA and other inflammatory mediators, such as activated complement, work synergistically to promote cellular injury.

Methods
Study design, settings, and participants. This prospective cohort study utilized cell-free plasma samples
that had been prospectively collected from 97 adult patients with confirmed COVID-19 presenting to
the Barnes-Jewish Hospital from March 15, 2020, to April 24, 2020. Eligible participants included
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Figure 5. Circulating MT-DNA levels have similar or improved accuracy over clinically utilized biomarkers for outcomes of severity in COVID-19.
Blood samples for determination of biomarkers levels were collected within 24 hours from hospital presentation. ROC curves in predicting the
outcomes (A) mortality, (B) admission to ICU, and (C) intubation based on MT-CYTB (red), reactive C protein (CRP) (blue), ferritin (black), lactic
acid dehydrogenase (LDH) (purple), and D-dimer (green) levels. AUC with 95% CI and P values for the different biomarkers are summarized in the
corresponding tables.

consented adults, greater than 18 years old, presenting with COVID-19 symptoms who received a
COVID-19 test at the time of hospital presentation that resulted in a COVID-19 diagnosis. Diagnosis of COVID-19 was based on a positive nasopharyngeal swab test. Excluded participants were
COVID-19–diagnosed patients who did not have plasma samples collected within 24 hours of time of
hospital presentation.
Outcome definition. Subjects were followed through June 29, 2020. The primary outcome was mortality.
The secondary outcomes included (a) the need for an ICU admission and (b) endotracheal intubation, as
well as the development of end organ dysfunction while in the ICU requiring (c) vasopressors and (d) RRT.
Subjects who were on dialysis prior to admission were excluded from the RRT outcome analysis. These
outcomes were abstracted utilizing an honest broker system from electronic medical records.
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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Figure 6. Circulating MT-DNA levels correlate with other emerging markers of inflammation and cytokines in COVID-19 patients. Scatter plots showing
the correlation between MT-CYTB and (A) IL-6, (B) C5b-9 (terminal complement complex), and (C) neutrophil-to-lymphocyte ratio (NLR), (D) CXCL9, (E)
CCL2, (F) CXCL10, (G) IL-1RA, (H) IL-2R, and (I) HGF. The degree of correlation was assessed using Spearman’s rank correlation coefficient test.

Sample collection and processing. MT-DNA and other cytokines were measured in cell-free plasma of
subjects within the first 24 hours of emergency department presentation. Blood samples were collected in
EDTA-containing vacutainers (BD Biosciences) and subjected to 2 rounds of centrifugation to generate
platelet poor plasma, first at 2500g for 20 minutes to generate plasma. The plasma was removed from
vacutainers and centrifuged at 13,000g in sterile nuclease-free eppendorf tubes (Thermo Fisher Scientific)
for 10 minutes to remove platelets. These platelet-poor specimens were then immediately stored at −80°C
JCI Insight 2021;6(4):e143299 https://doi.org/10.1172/jci.insight.143299
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until further analysis. Concurrently measured clinical markers (i.e., CRP, ferritin, lactate dehydrogenase,
D-dimer) were obtained from the electronic medical record.
MT-DNA quantification. MT-DNA quantification real-time PCR was performed in a Bio-Rad
CFX-Connect machine using reaction mixture containing 0.1 μL of cell-free plasma, 10 μL iQ SYBR
Green Supermix (Bio-Rad), 0.5 μL of 5 μM forward and reverse primers, and 8.9 μL H2O. Assays were
performed in triplicate under the following conditions: 1 cycle at 95°C for 3 minutes, then up to 40 cycles
at 95°C for 10 seconds and 55°C for 30 seconds, and then a melt curve was performed from 65°C to 95°C
(0.5°C every 5 seconds). Primers for human cytochrome b (CYB; forward 5′-ATGACCCCAATACGCAAAAT-3′ and reverse 5′-CGAAGTTTCATCATGCGGAG-3′) and human cytochrome c oxidase subunit III (COX3: forward 5′-ATGACCCACCAATCACATGC-3′ and reverse 5′-ATCACATGGCTAGGCCGGAG-3′) were synthesized by Integrated DNA Technologies. Copy number was
estimated by comparison to a real-time PCR standard amplification curve. To generate the standard
curve, selected regions of human purified MT-DNA containing the target sequences for MT-CYTB (forward 5′-ATGACCCCAATACGCAAAAT-3′ and reverse 5′-GACGGATCGGAGAATTGTGT-3′) and
MT-COX3 (forward 5′-ATGACCCACCAATCACATGC-3′ and reverse 5′-ATCAATAGATGGAGACATAC-3′) were amplified by PCR under the following conditions: initial denaturation at 94°C for 2
minutes, then up to 35 cycles of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds,
and extension at 72°C for 1 minute. After amplification, MT-DNA was gel purified, extracted, and
quantified by NanoDrop (Thermo Fisher Scientific). Serial dilutions were then used to calibrate the
real-time PCR standard curves. Final results were expressed as copy number of MT-DNA, and their
absolute values were converted to log10 before statistical analysis.
Quantification of cytokines and complement activation. Cell-free plasma was analyzed using a Cytokine
35-Plex Human Panel, which provides simultaneous measurement of 35 cytokines (Thermo Fisher
Scientific). The assay was performed in accordance with manufacturer’s instructions with each subject
sample performed in duplicate and then analyzed on a Luminex FLEXMAP 3D instrument. Internal
validation control with every plate also was run in duplicate. Complement activation was assessed
in cell-free plasma specimens (not previously thawed) using the soluble C5b-9 assay (BD Biosciences
OptEIA Human C5b-9 ELISA set).
Statistics. Continuous variables were reported as median (interquartile range). The predictive value of
each biomarker was expressed as AUC derived from the relative ROC curve. Spearman r coefficient was
calculated to estimate the correlation between 2 continuous variables. Univariate logistic regression analysis was used to calculate the unadjusted ORs. Independent variables known to have a biological relationship with the outcomes were selected a priori based on existing literature for the multivariate logistic
model to calculate the adjusted ORs (72–74). Model diagnostics were performed with Corrected Akaike
Information Criterion, log likelihood, and model deviance. The MT-DNA was log (base 10) transformed
prior to data analysis to better meet model assumptions. To facilitate interpretation for this variable, the
OR estimates were raised to the 0.5 power, which is interpreted as the increase in the odds of the outcome
for each 0.5 change in MT-DNA on the log scale. All the statistical analyses were calculated and all figures
were prepared using GraphPad Prism 8.4.2 (GraphPad Software Inc.). For all the analyses, a P value less
than 0.05 was considered significant.
Study approval. The study was approved by the Washington University School of Medicine Institutional
Review Board (ID 202004091 and 202003085). Written informed consent was obtained from all subjects.
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